5 things you should know before the stock market opens on Friday October 22nd

Here are the key news, trends, and analysis investors need to start their trading day: 1. Stock futures mixed after the record close of the S&P 500 Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, USA on October 20, 2021. Brendan McDermid | Reuters US stock futures … Read more

Is a Moderna, Pfizer, or J&J Covid-19 Booster Shot Best For You? What You Should Know About Mixing Vaccines – The Wall Street Journal

Is a Moderna, Pfizer, or J&J Covid-19 Booster Shot Best For You? What You Should Know About Mixing VaccinesThe Wall Street Journal FDA approves Covid-Booster for J&J, Moderna and allows “mix and match” recordingsCNBC television Opinion | Leana Wen: Why I chose the Pfizer booster after the Johnson & Johnson vaccineThe Washington Post 100% of … Read more

How rising Covid cases in Great Britain could be “a compelling argument for boosters”

Former Obama White House Political Director Dr. Kavita Patel explained why the rising number of Covid cases in the UK could be a compelling argument in favor of booster vaccinations. “What is happening is … this real-world experiment where AstraZeneca becomes less effective and they haven’t brought their boosters to market,” said Patel during an … Read more

‘Stop freaking out about inflation’ and buy these companies

CNBC’s Jim Cramer on Tuesday compiled a list of companies that are benefiting from inflation, suggesting that investors are looking for performance there while price pressures weigh on other parts of the market. “Don’t fall into the trap of believing that the entire market will be destroyed by ongoing inflation, with the exception of oils,” … Read more

5 things you should know before the stock market opens on Tuesday October 19th

Here are the top news, trends, and analysis investors need to start their trading day: 1. Stock futures jump to S&P 500, Nasdaq posts 4-day profit streaks Traders operate on the floor of the New York Stock Exchange (NYSE) on October 12, 2021. Brendan McDermid | Reuters 2. Dow stocks J&J and P&G each fall … Read more

Procter & Gamble, Johnson & Johnson, Travelers and More

Take a look at some of the biggest movers in the premarket: Procter & Gamble (PG) – The consumer goods giant beat estimates by 2 cents per share with quarterly earnings of $ 1.61 per share. Sales also exceeded Wall Street forecasts. However, P&G said it was facing rising raw material and transportation costs and … Read more

Covid and Johnson & Johnson JNJ Profit Q3 2021

Johnson & Johnson said in its earnings report on Tuesday that it sold $ 502 million of its Covid-19 vaccine in the third quarter, beating Wall Street’s earnings expectations. According to Refinitiv’s average estimates, J&J has fared compared to Wall Street expectations as follows: Adjusted earnings per share: $ 2.60 per share versus expected $ … Read more

Fauci says FDA data shows the J&J vaccine should have been two shots

President BidenJoe BidenPressure Grows For Breakthrough In Biden Agenda Talks State Education Board Leaves National Association, Says They Called Parents Local Terrorists Sunday Shows Preview: Supply Chain Crisis Threatens Christmas Sales; Uncertainty as to whether the US can sustain the nationwide downward trend in COVID-19 cases MOREthe senior medical advisor, Anthony FauciAnthony FauciSunday Preview: Supply … Read more

The Dow is on track for its best October in 6 years and third quarter results have been strong so far. What could go wrong?

A traditionally troubled month turns out to be anything but for the stock market … until now. Given the end of last month and the start of the first full week of October, who would have thought that investors would be sitting nicely now. Dennis Gartman certainly not. But here we are. Look at us … Read more

Scientists are still concerned about the risk of an mRNA Covid booster causing heart inflammation in young adults, says Dr. Ofer Levy

The risk of mRNA Covid booster vaccinations causing heart inflammation in young adults continues to worry top scientists considering whether to approve a third dose for people over the age of 12, said Dr. Ofer Levy, a voting member of the Advisory Board of the Food and Drug Administration, on Friday. Levy, the director of … Read more